Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02992327 · ClinicalTrials.gov registry record
Biomarker Levels as A Predictor of Concussion Severity OUTcomes (BlacOut)
A clinical trial of Concussion, Mild and Neurocognitive Dysfunction, sponsored by HealthPartners Institute.
- Completed
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT02992327 is a study of Concussion, Mild and Neurocognitive Dysfunction that has completed, run by HealthPartners Institute. The registered enrollment target is 100 participants, below the 198-participant average among 18 other Concussion, Mild trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02992327, a study of Concussion, Mild and Neurocognitive Dysfunction, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall research aim of this pilot study is to determine if the structural brain protein calpain-cleaved αII-spectrin N-terminal fragment (SNTF) can be used as a blood biomarker to accurately identify patients who will have more severe symptoms and reduced neurocognitive functioning after sustaining a concussion. Concussion is also referred to as mild traumatic brain injury (mTBI) in the literature. Both terms will be used interchangeably throughout this application.
Conditions Studied
Study Locations (1)
Minnesota
- Regions Hospital - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2015-08-30 |
| Est. Completion | 2018-08-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02992327
The ClinicalTrials.gov registry entry for NCT02992327 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 18 other Concussion, Mild trials with a reported enrollment target (49% lower). The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Concussion, Mild appearing as the primary indexed condition, and to 0 interventions.
NCT02992327 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02992327 about?
NCT02992327 is a clinical study titled "Biomarker Levels as A Predictor of Concussion Severity OUTcomes (BlacOut)". The overall research aim of this pilot study is to determine if the structural brain protein calpain-cleaved αII-spectrin N-terminal fragment (SNTF) can be used as a blood biomarker to accurately identify patients who will have more severe symptoms and reduced neurocognitive functioning after sustai...
What is the current status of trial NCT02992327?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2015-08-30. Estimated completion is 2018-08-06.
What conditions does trial NCT02992327 study?
This clinical trial studies the following conditions: Concussion, Mild, Neurocognitive Dysfunction.
Who is sponsoring clinical trial NCT02992327?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02992327 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Concussion, Mild
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acceptance and Commitment Therapy Integrated Vestibular Rehabilitation (ACTIVE) RCT
RECRUITING · NA
-
Eye Recovery Automation for Post Injury Dysfunction (iRAPID)
RECRUITING · NA
-
BCAAs in Concussion 2.0
RECRUITING · Phase 2
-
Facilitating Access to Specialty Treatment
RECRUITING · NA
-
Concussion Treatment in Older Adults
RECRUITING · NA
-
Poly-omic Predictors of Symptom Duration and Recovery for Adolescent Concussion
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.